193 related articles for article (PubMed ID: 22008843)
21. Omega 3 - Omega 6: What is right for the liver?
El-Badry AM; Graf R; Clavien PA
J Hepatol; 2007 Nov; 47(5):718-25. PubMed ID: 17869370
[TBL] [Abstract][Full Text] [Related]
22. The role of the lipogenic pathway in the development of hepatic steatosis.
Postic C; Girard J
Diabetes Metab; 2008 Dec; 34(6 Pt 2):643-8. PubMed ID: 19195625
[TBL] [Abstract][Full Text] [Related]
23. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression.
Sekiya M; Yahagi N; Matsuzaka T; Najima Y; Nakakuki M; Nagai R; Ishibashi S; Osuga J; Yamada N; Shimano H
Hepatology; 2003 Dec; 38(6):1529-39. PubMed ID: 14647064
[TBL] [Abstract][Full Text] [Related]
24. The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis.
Sozio MS; Liangpunsakul S; Crabb D
Semin Liver Dis; 2010 Nov; 30(4):378-90. PubMed ID: 20960377
[TBL] [Abstract][Full Text] [Related]
25. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
Geisler CE; Renquist BJ
J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
[TBL] [Abstract][Full Text] [Related]
26. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
Verna EC; Berk PD
Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
[TBL] [Abstract][Full Text] [Related]
27. Omega-3 long chain fatty acid synthesis is regulated more by substrate levels than gene expression.
Tu WC; Cook-Johnson RJ; James MJ; Mühlhäusler BS; Gibson RA
Prostaglandins Leukot Essent Fatty Acids; 2010 Aug; 83(2):61-8. PubMed ID: 20573490
[TBL] [Abstract][Full Text] [Related]
28. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation.
Reddy JK; Rao MS
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G852-8. PubMed ID: 16603729
[TBL] [Abstract][Full Text] [Related]
29. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD).
Ahmed MH; Byrne CD
Drug Discov Today; 2007 Sep; 12(17-18):740-7. PubMed ID: 17826687
[TBL] [Abstract][Full Text] [Related]
30. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S
Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids.
Davidson MH
Am J Cardiol; 2006 Aug; 98(4A):27i-33i. PubMed ID: 16919514
[TBL] [Abstract][Full Text] [Related]
32. Some novel insights into the pathogenesis of alcoholic steatosis.
Lakshman MR
Alcohol; 2004 Aug; 34(1):45-8. PubMed ID: 15670665
[TBL] [Abstract][Full Text] [Related]
33. Adiponectin and alcoholic fatty liver disease.
Rogers CQ; Ajmo JM; You M
IUBMB Life; 2008 Dec; 60(12):790-7. PubMed ID: 18709650
[TBL] [Abstract][Full Text] [Related]
34. Non-alcoholic fatty liver disease.
Smith BW; Adams LA
Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
[TBL] [Abstract][Full Text] [Related]
35. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
36. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease.
Videla LA; Rodrigo R; Araya J; Poniachik J
Trends Mol Med; 2006 Dec; 12(12):555-8. PubMed ID: 17049925
[TBL] [Abstract][Full Text] [Related]
37. Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model.
Matsunami T; Sato Y; Ariga S; Sato T; Shimomura T; Kashimura H; Hasegawa Y; Yukawa M
Metabolism; 2011 Jun; 60(6):805-14. PubMed ID: 20846698
[TBL] [Abstract][Full Text] [Related]
38. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease.
Kohjima M; Higuchi N; Kato M; Kotoh K; Yoshimoto T; Fujino T; Yada M; Yada R; Harada N; Enjoji M; Takayanagi R; Nakamuta M
Int J Mol Med; 2008 Apr; 21(4):507-11. PubMed ID: 18360697
[TBL] [Abstract][Full Text] [Related]
39. [Insulin resistance].
Tamura Y; Kawamori R
Nihon Rinsho; 2006 Jun; 64(6):1071-4. PubMed ID: 16768111
[TBL] [Abstract][Full Text] [Related]
40. Biosynthesis and bioavailability of long-chain polyunsaturated fatty acids in non-alcoholic fatty liver disease.
Gormaz JG; Rodrigo R; Videla LA; Beems M
Prog Lipid Res; 2010 Oct; 49(4):407-19. PubMed ID: 20553760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
